The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV

Nephrology Dialysis Transplantation

Volumn 19, Issue 2, 2004, Pages 386-390

  Hannon, Heidi ^a   Bagnis, Corinne Isnard ^a   Benhamou, Yves ^a   Beaufils, Hélène ^b   Sullivan, Mark ^c   Brosgart, Carol ^c   Izzedine, Hassan ^a   Poynard, Thierry ^a   Deray, Gilbert ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c GILEAD SCIENCES   (United States)

Author keywords

Adefovir dipivoxil; Hepatitis B; HIV infection; Hypophosphataemia; Nephrotoxicity; Renal tolerance; Tubulopathy

Indexed keywords

ABACAVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AMPRENAVIR; ANTIRETROVIRUS AGENT; CREATININE; DIDANOSINE; EFAVIRENZ; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; IMMUNOMODULATING AGENT; INDINAVIR; INTERLEUKIN 2; LAMIVUDINE; LOBUCAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PHOSPHATE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; STEROID; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSURIA; ELECTROLYTE BALANCE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION; KIDNEY TUBULE DISORDER; LOW DRUG DOSE; MALE; METABOLIC DISORDER; NEPHROTOXICITY; NONHUMAN; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; SUPERINFECTION; VIRUS PATHOGENESIS; VIRUS RESISTANCE;

ADENINE; ADMINISTRATION, ORAL; ADULT; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; LAMIVUDINE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PHOSPHONIC ACIDS; PROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 1042280351     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg505     Document Type: Article

References (13)

1. Lai CL, Chien RN, Leung NW el al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-68
2. Kahn J, Lagakos S et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. J Am Med Assoc 1999; 282: 2305-2312
3. Fisher EJ, Chaloner K et al. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS 2001; 15: 1695-1700
4. Benhamou Y, Bochet M et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358: 718-723
5. Peters MG, Singer G et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation 1999; 68: 1912-1914
6. Perrillo R, Schiff E et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 129-134
7. Gilson RJ, Chopra KP et al. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepat 1999; 6: 387-395
8. Marcellin P, Chang T-T, Lim SG et al. A double-blind, randomized, placebo-controlled study of adefovir dipivoxil for the treatment of patients with HBeAg+ chronic hepatitis B. Hepatology 2001; 4 [Part 2]: 340A
9. Schiff E, Neuhaus P, Tillman H et al. The safety and efficacy of adefovir dipivoxil (ADV) for the treatment of lamivudine resistant HBV in patients post liver transplantation. Hepatology 2001; 4 [Part 2]: 446A
10. Deeks SG, Collier A, Lalezari J et al. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy in infected adults: a randomized, double blind, placebo-controlled trial. J Infect Dis 1997; 176: 1517-1523
11. Tanji N, Tanji K, Kambham N, Markowitz GS, Bell A, D'agati V. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol 2001; 32: 734 740
12. Cundy KC, Barditch-Crovo P et al. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 1995; 39: 2401-2405
13. Cihlar T, Lin DC et al. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mal Pharmacol 1999; 56: 570-580